Up-front ixazomib in older patients with myeloma

In this issue of Blood, Facon et al report the results of the large randomized Tourmaline 2 trial including 705 transplantation-ineligible patients with newly diagnosed multiple myeloma, in which they show that the addition of oral ixazomib to the standard-treatment doublet of lenalidomide plus low-dose dexamethasone (Rd) results in a clinically meaningful progression-free survival (PFS) benefit.(1)